We read with interest the article by Scalzo et al,1 in which the authors report a perceived unexpected corticosteroid-resistant early post–kidney transplant acute cellular rejection occurring within 48 hours in a low-immunologic-risk recipient receiving maintenance daratumumab for multiple myeloma. They conclude that daratumumab could be the risk factor for this rejection. It could be inferred by readers that similar patients should receive T cell–depleting agents at time of induction of immunosuppression.